Deutsche Bank keeps Buy rating and EUR 47 target for Qiagen stock

Published on 10/02/2026 at 13:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 535.00 million in the second quarter of 2026. Qiagen stock costs EUR 37.59 on October 2, 2026 versus EUR 37.51.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen (ISIN NL0015002SN0) was trading at EUR 37.59 at Lang and Schwarz on October 2, 2026, up 0.21 percent from the EUR 37.51 prior close. According to Finanznachrichten on September 24, 2026, Deutsche Bank Research kept its Buy rating and EUR 47.00 price target ahead of Qiagen's third-quarter results.

Deutsche Bank sees EUR 47 target

The target implies that the analyst view remains above the German-market euro quote, while the recommendation is tied to expectations that Qiagen will approach the upper end of its outlook range. The September 24 note also pointed to strategic reviews as an area for investor attention, giving the rating a specific operational focus.

Second-quarter figures beat estimates

MarketBeat reported that Qiagen delivered USD 535.04 million of revenue in the second quarter of 2026 versus USD 527.50 million expected. Adjusted earnings per share reached USD 0.62, beating the USD 0.60 consensus by USD 0.02.

Zacks said Sample technologies revenue rose 9.00 percent at constant exchange rates to USD 182.00 million in the second quarter, while PCR and nucleic acid amplification revenue fell 7.00 percent to USD 74.00 million. The contrast shows why the growth-pillar mix matters more than the headline revenue increase of 0.30 percent from the year-earlier quarter.

Outlook remains the next test

Zacks reported that Qiagen reaffirmed 2026 constant-currency sales growth of 1-2 percent and adjusted earnings of at least USD 2.43 per share. Management also expects third-quarter sales growth of 1-2 percent and adjusted earnings of at least USD 0.62 per share, while second-half sales growth is projected at 3-4 percent.

On the primary listing, Qiagen trades on the NYSE under QGEN, while its German listing is QIA on Xetra. The NYSE quote was last at USD 43.07 on October 1, 2026 at 4:00 p.m. EDT, against a 52-week range of USD 32.53 to USD 57.82 and a market capitalization of USD 8.7 billion. Qiagen's investor-relations page identifies both listings and describes its sample-to-insight business serving life sciences and molecular diagnostics.

Leadership date adds a second event

According to Business Wire on September 18, 2026, Qiagen scheduled an extraordinary general meeting for November 6, 2026, to vote on Jonathan M. Pratt's appointment to the managing board after he became chief executive officer on September 1, 2026. The meeting date gives investors a defined corporate milestone alongside the upcoming quarterly reporting cycle.

Qiagen stock stays below the target

Qiagen was trading at EUR 37.59 at Lang and Schwarz on October 2, 2026 at 1:45 p.m. CEST, plus 0.21 percent versus the EUR 37.51 prior close. The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.